A Meta-analysis on curative effect and safety of Qili Qiangxin Capsules in treatment of dilated cardiomyopathy
Li Tao
Sun Zhonghua
Zhao Bingbing
Abstract：Objective To review the curative effect and safety of Qili Qiangxin Capsules in treatment of dilated cardiomyopathy (DCM). Methods The literature of randomized controlled trials (RCT) about treatment of DCM with Qili Qiangxin Capsules were retrieved with computer and handwork, and all data was given a Meta-analysis by using RevMan5.3 software. Results There were 12 RCT included and totally 736 cases of DCM involved in. The results of Meta-analysis showed that the total effective rate was higher in routine Western drugs+Qili Qiangxin Capsules group and Western drug group (RR=1.36, 95%CI: 1.16~1.59). The left ventricular ejection fraction (LVEF, MD=5.35, 95%CI: 3.74~6.95) was improved, left ventricular end-diastolic inner diameter (LVEDD, MD=3.97, 95%CI: 2.23~5.70) and left ventricular end-systolic diameter (LVESD, MD=2.88, 95%CI: 1.72~4.03) were reduced, and 6-minute walk test (6MWT, MD=43.86, 95%CI: 28.02~59.56) was increased. The levels of brain natriuretic peptide (BNP, MD=43.86, 95%CI: 28.02~66.88), tumor necrosis factor (TNF, MD=43.86, 95%CI: 28.02~66.88) and high mobility group protein-B1 (HMG-B1, MD=4.36, 95%CI: 2.73~5.98) were decreased. There was no significant difference in incidence of adverse reactions between 2 groups (RR=0.99, 95%CI: 0.35~2.80). Conclusion Qili Qiangxin Capsules can improve the heart function and relieve clinical symptoms with higher safety in DCM patients, while its long-term curative effect is needed more clinical studies.
Keywords：Qili Qiangxin CapsulesDilated cardiomyopathyMeta-analysis
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 1305-1309 )